abs202.txt	glioblastoma	(gbm)		the	most	common	and	aggressive	primary	brain	cancer		carriesa	life	expectancy	of	12-15	months		the	short	life	expectancy	is	due	in	part	tothe	inability	of	the	current	treatment		consisting	of	surgical	resection	followedby	radiation	and	chemotherapy		to	eliminate	invasive	tumor	foci		treatment	ofthese	foci	may	be	improved	with	tumoricidal	human	mesenchymal	stem	cells	(mscs)	mscs	exhibit	potent	tumor	tropism	and	can	be	engineered	to	express	therapeuticproteins	that	kill	tumor	cells		advancements	in	preclinical	models	indicate	thatsurgical	resection	induces	premature	msc	loss	and	reduces	therapeutic	efficacy	efficacy	of	msc	treatment	can	be	improved	by	seeding	mscs	on	a	biodegradablepoly(lactic	acid)	(pla)	scaffold		msc	delivery	into	the	surgical	resection	cavityon	a	pla	scaffold	restores	cell	retention		persistence		and	tumor	killing		tostudy	the	effects	of	msc-seeded	pla	implantation	on	gbm		an	accurate	preclinicalmodel	is	needed		here	we	provide	a	preclinical	surgical	protocol	for	image-guidedtumor	resection	of	gbm	in	immune-deficient	mice	followed	by	msc-seeded	scaffoldimplantation		mscs	are	engineered	with	lentiviral	constructs	to	constitutivelyexpress	and	secrete	therapeutic	tnfÎ±-related	apoptosis-inducing	ligand	(trail)	aswell	as	green	fluorescent	protein	(gfp)	to	allow	fluorescent	tracking		similarly	the	u87	tumor	cells	are	engineered	to	express	mcherry	and	firefly	luciferase	providing	dual	fluorescent/luminescent	tracking		while	currently	used	forinvestigating	stem	cell	mediated	delivery	of	therapeutics		this	protocol	could	bemodified	to	investigate	the	impact	of	surgical	resection	on	other	gbminterventions	
